Summary & Overview
CPT 36522: Extracorporeal Photopheresis, Therapeutic Apheresis
CPT code 36522 denotes extracorporeal photopheresis, a therapeutic apheresis procedure in which a patient’s white blood cells are exposed to 8–methoxypsoralen (8–MOP) and ultraviolet A (UVA) light prior to reinfusion. The code captures a complex, device-dependent therapy used for select immune-mediated and hematologic conditions; its accurate coding supports appropriate clinical documentation and payer adjudication across hospital outpatient and specialized infusion settings. Nationally, extracorporeal photopheresis remains a high-cost, resource-intensive service with variable coverage policies and utilization patterns among major payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of clinical context for the procedure, common billing modifiers observed on claims, payer coverage characteristics, and benchmarking information where available. The publication summarizes coding guidance, site-of-service considerations, and implications for billing workflows and prior authorization processes. Data not available in the input is noted where relevant. This briefing is intended to inform coding teams, revenue cycle managers, and clinical leaders about the operational and policy factors associated with use of CPT code 36522 at a national level.
Billing Code Overview
CPT code 36522 describes extracorporeal photopheresis, a therapeutic apheresis procedure in which a patient’s white blood cells are collected, treated with the photosensitizing agent 8–methoxypsoralen (8–MOP), and exposed to ultraviolet A (UVA) light before being reinfused. This procedure is a specialized immunomodulatory therapy used in select hematologic, oncologic, and immune-mediated conditions.
-
Service type: Therapeutic apheresis with extracorporeal photoactivation
-
Typical site of service: Hospital outpatient departments or ambulatory infusion/pheresis centers where apheresis equipment and photopheresis devices are available
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant presents with progressive skin sclerosis and steroid-refractory symptoms. The hematology/oncology team orders extracorporeal photopheresis (ECP) as an immunomodulatory therapy. The clinical workflow includes venous access placement (peripheral or central), leukapheresis to collect peripheral blood mononuclear cells, ex vivo exposure of collected cells to 8–methoxypsoralen (8–MOP) followed by UVA irradiation, and reinfusion of treated cells. Each ECP session typically requires pre-procedure assessment (vital signs, anticoagulation review), apheresis nursing and physician oversight, monitoring during the procedure for hemodynamic or access complications, and post-procedure observation for adverse effects like hypotension or infection. Treatments are often administered in outpatient infusion centers or hospital apheresis suites on multiple consecutive days or at regular intervals over weeks to months depending on clinical response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal or routine service | When ECP is performed without complications and as the primary service. |
22 |